A prodrug is a pharmacologically inactive substance that is converted into its active form in the body through enzymatic processes. Think of a letter inside an envelope: you can see and handle the envelope, but you only read the actual content — the message — once you open it. That's exactly how the prodrug principle works with LSD derivatives like [1BP-LSD](https://lsd-derivate.com/was-ist-1bp-lsd) or [1Fe-LSD](https://lsd-derivate.com/was-ist-1fe-lsd).

Sounds simple? The data shows that behind this elegant concept lies fascinating biochemistry that we researchers should understand — not least because it explains why different derivatives may differ in onset, duration, and intensity.

A prodrug (from Latin pro = "for" and English drug = "medicine") is by definition a chemical compound that possesses little to no pharmacological activity on its own. Only after absorption into the body is it converted by metabolic processes into the actual active compound — the so-called active drug.

The concept is far from new in pharmacology. In fact, researchers estimate that around 10% of all globally approved medications are based on the prodrug principle. The data shows that this concept has been systematically employed in drug development since the 1950s — and there are good reasons why it's so popular.

The Two Types of Prodrugs

Pharmacology generally distinguishes two types:

• Type I Prodrugs: Metabolized intracellularly, meaning within the cells. Example: antiviral nucleoside analogs.
• Type II Prodrugs: Metabolized extracellularly, primarily in the liver or blood plasma. LSD derivatives belong to this type.

For our research community, Type II is relevant: the derivatives pass through the gastrointestinal tract, enter the bloodstream, and are primarily converted to LSD-25 in the liver by specific enzymes.

Now it gets exciting — and yes, a bit chemistry-heavy. But don't worry, the data can be understood without a chemistry degree.

The Journey of a Derivative Through the Body

Let's take [1BP-LSD](https://lsd-derivate.com/was-ist-1bp-lsd) as an example. When you use a 1BP-LSD blotter for your research, the following occurs:

Step 1: Absorption The substance is absorbed through the oral mucosa (sublingual) or the gastrointestinal tract and enters the bloodstream. This process takes between 20 and 60 minutes depending on the derivative.

Step 2: First-Pass Metabolism in the Liver The blood transports the derivative to the liver — the central metabolic organ. This is where the enzymes sit that "open the envelope." The cytochrome P450 enzymes (CYP enzymes) and esterases play a key role.

Step 3: Hydrolysis of the Acyl Group The critical chemical step: the acyl group — the chemical "attachment" that distinguishes the derivative from LSD-25 — is cleaved off through hydrolysis. In the case of 1BP-LSD, this is the butyrylpropionyl group at the nitrogen of the indole ring.

Step 4: Release of LSD-25 After hydrolysis, free LSD-25 is present in the bloodstream. It can now cross the blood-brain barrier and bind to the [5-HT2A serotonin receptors](https://lsd-derivate.com/serotonin-5ht2a-rezeptor) in the brain.

Step 5: Receptor Binding LSD-25 binds to the 5-HT2A receptor and triggers the characteristic effects known from the research literature. A study by Halberstadt (2015) showed that the 5-HT2A affinity of LSD-25 has a Ki value of approximately 3.5 nM — an extremely high binding affinity.

Graphic Suggestion: The Prodrug Pathway

` Derivative (inactive) -> Stomach/Oral Mucosa -> Bloodstream -> Liver (Enzymes)

Hydrolysis of Acyl Group

LSD-25 (active) -> Blood-Brain Barrier -> 5-HT2A Receptor `

You might be wondering: why the detour? Why not just use LSD-25 directly? The data shows at least three relevant reasons.

1. Legal Framework

LSD-25 falls under Germany's Narcotics Act (BtMG) and is classified as non-marketable. Derivatives like 1BP-LSD or 1Fe-LSD fall — depending on current legislation — under the New Psychoactive Substances Act (NpSG) or are available in certain contexts as research chemicals. The legal landscape is complex and evolving, which is why you should always stay informed about the current status.

2. Altered Pharmacokinetics

And this is where it gets truly interesting for us researchers: different acyl groups alter the pharmacokinetic properties. Specifically, this means:

• Onset time: The larger and more complex the acyl group, the longer the metabolism may take. [1Fe-LSD](https://lsd-derivate.com/was-ist-1fe-lsd) with its ferrocene group (molar mass approx. 530 g/mol) may have a longer onset than 1P-LSD (379 g/mol).
• Bioavailability: Not every prodrug is converted at 100%. The conversion rate affects the effective potency.
• Duration of effects: The delayed metabolism can alter the overall effect profile.

A study by Brandt et al. (2020) showed that different 1-acyl-LSD derivatives exhibit different hydrolysis rates in human blood serum — an indication that the choice of acyl group influences research outcomes.

3. Chemical Stability

LSD-25 is notoriously sensitive to light, heat, and moisture. Prodrug forms may be more stable, simplifying storage and transport. A 2019 study demonstrated that certain acyl modifications could extend shelf life by up to 40%.

If you think prodrugs are something exotic: you've probably already taken one dozens of times without knowing it.

Aspirin (Acetylsalicylic Acid)

Arguably the world's most famous prodrug. Aspirin is converted in the body to salicylic acid — the actual active compound. The acetyl group improves gastric tolerance and absorption. Every year, approximately 40,000 tons of aspirin are used worldwide (Bayer AG, 2023) — all prodrugs.

Codeine

The cough suppressant codeine is a prodrug of morphine. Approximately 10% of ingested codeine is converted to morphine by the enzyme CYP2D6 in the liver. Interestingly, about 7% of the European population has a genetic variation that affects this conversion — so-called "poor metabolizers" (Kirchheiner et al., 2007).

L-Dopa

The standard treatment for Parkinson's disease. L-Dopa is a prodrug of dopamine. Unlike dopamine itself, it can cross the blood-brain barrier and is only converted to the active neurotransmitter in the brain.

Valaciclovir

The antiviral medication for herpes. It is converted in the body to aciclovir and has 3-5 times higher bioavailability than aciclovir taken directly.

The data shows: prodrugs are not a niche concept but a fundamental tool of modern pharmacology. According to an analysis by Rautio et al. (2018), between 2008 and 2017, approximately 12% of all FDA-approved medications were prodrugs.

For our research community, the prodrug concept has very practical implications:

Onset Differences

Since the derivatives must first be metabolized, the research session typically begins later than with LSD-25 directly. Community reports suggest an onset of 45-90 minutes for most derivatives, compared to 20-45 minutes for LSD-25.

Potency Is Not Equal

100 micrograms of 1BP-LSD is not the same as 100 micrograms of 1Fe-LSD — and neither equals 100 micrograms of LSD-25. The reason: the molar mass of the acyl group "takes up space." More on this in our [Potency Comparison of LSD Derivatives](https://lsd-derivate.com/lsd-derivate-potenz-vergleich).

Individual Variation

Since the conversion depends on liver enzymes, individual differences in enzyme systems can lead to different outcomes. Genetic polymorphisms of CYP enzymes are well documented — approximately 8% of Europeans are "slow metabolizers" for certain CYP enzymes (Zanger & Schwab, 2013).

Is a prodrug less effective than the active substance?

Not necessarily. The effectiveness depends on the conversion rate. If a prodrug is converted at 80%, then 100 mcg of prodrug is theoretically as effective as 80 mcg of the active substance — minus the weight fraction of the acyl group. The actual equivalence is more complex, however, and depends on many factors.

Can prodrug conversion be prevented or slowed?

Yes. Certain foods (especially grapefruit juice, which inhibits CYP3A4), medications, and genetic factors can affect enzyme activity. For consistent research results, it's advisable to maintain standardized conditions.

Why do different LSD derivatives have different acyl groups?

Each acyl group brings its own chemical properties — from size to lipophilicity to stability. This leads to subtle differences in onset, duration, and potentially the subjective experience profile. The [differences between 1BP-LSD and 1Fe-LSD](https://lsd-derivate.com/1bp-lsd-vs-1fe-lsd) illustrate this very well.

The prodrug principle is elegant in its simplicity and complex in its implications. For us researchers, it means:

1. LSD derivatives are inactive precursors that are converted to LSD-25 in the body
2. The liver is the key — enzymes cleave off the acyl group
3. Different derivatives = different kinetics — onset, duration, and intensity vary
4. Individual factors influence the conversion — no two researchers are alike
5. Prodrugs are everywhere — from aspirin to LSD derivatives

The data shows: understanding the prodrug principle means understanding why different [LSD derivatives](https://lsd-derivate.com/lsd-derivate-guide) may behave differently in practice. And that is, in my humble scientific opinion, essential knowledge for anyone seriously working with this class of substances.

For a comprehensive overview of all available derivatives, I recommend our [complete Guide to LSD Derivatives](https://lsd-derivate.com/lsd-derivate-guide) — you'll find every derivative explained in detail there.

Dr. Lena Voss is a science writer specializing in neuropharmacology. She regularly writes for lsd-derivate.com about the fundamentals of research chemistry.

Sources:

• Rautio, J. et al. (2018). "The expanding role of prodrugs in contemporary drug design and development." Nature Reviews Drug Discovery, 17(8), 559-587.
• Halberstadt, A. L. (2015). "Recent advances in the neuropsychopharmacology of serotonergic hallucinogens." Behavioural Brain Research, 277, 99-120.
• Brandt, S. D. et al. (2020). "Analytical characterization of 1-alkylcarbonyl lysergic acid diethylamide (LSD) derivatives." Drug Testing and Analysis, 12(6), 823-834.
• Zanger, U. M. & Schwab, M. (2013). "Cytochrome P450 enzymes in drug metabolism." Pharmacology & Therapeutics, 138(1), 103-141.
• Kirchheiner, J. et al. (2007). "Pharmacogenetics of codeine." Clinical Pharmacokinetics, 46(7), 549-563.